RU2012108439A - Способы лечения опухолей головного мозга - Google Patents
Способы лечения опухолей головного мозга Download PDFInfo
- Publication number
- RU2012108439A RU2012108439A RU2012108439/15A RU2012108439A RU2012108439A RU 2012108439 A RU2012108439 A RU 2012108439A RU 2012108439/15 A RU2012108439/15 A RU 2012108439/15A RU 2012108439 A RU2012108439 A RU 2012108439A RU 2012108439 A RU2012108439 A RU 2012108439A
- Authority
- RU
- Russia
- Prior art keywords
- use according
- formulation
- sodium meta
- brain
- meta arsenite
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 210000004556 brain Anatomy 0.000 title 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims abstract 12
- 238000009472 formulation Methods 0.000 claims abstract 10
- 239000000203 mixture Substances 0.000 claims abstract 10
- PTLRDCMBXHILCL-UHFFFAOYSA-M sodium arsenite Chemical compound [Na+].[O-][As]=O PTLRDCMBXHILCL-UHFFFAOYSA-M 0.000 claims abstract 10
- 239000003814 drug Substances 0.000 claims abstract 8
- 229940079593 drug Drugs 0.000 claims abstract 6
- 238000001990 intravenous administration Methods 0.000 claims abstract 6
- 230000000973 chemotherapeutic effect Effects 0.000 claims abstract 4
- 239000000126 substance Substances 0.000 claims abstract 4
- 206010003571 Astrocytoma Diseases 0.000 claims abstract 2
- 208000000172 Medulloblastoma Diseases 0.000 claims abstract 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims abstract 2
- 101710183280 Topoisomerase Proteins 0.000 claims abstract 2
- 229940100198 alkylating agent Drugs 0.000 claims abstract 2
- 239000002168 alkylating agent Substances 0.000 claims abstract 2
- 230000003432 anti-folate effect Effects 0.000 claims abstract 2
- 229940127074 antifolate Drugs 0.000 claims abstract 2
- 239000002246 antineoplastic agent Substances 0.000 claims abstract 2
- 230000008499 blood brain barrier function Effects 0.000 claims abstract 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract 2
- 239000004052 folic acid antagonist Substances 0.000 claims abstract 2
- 201000002222 hemangioblastoma Diseases 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 206010027191 meningioma Diseases 0.000 claims abstract 2
- 208000007538 neurilemmoma Diseases 0.000 claims abstract 2
- 206010073131 oligoastrocytoma Diseases 0.000 claims abstract 2
- 206010039667 schwannoma Diseases 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24364809P | 2009-09-18 | 2009-09-18 | |
| US61/243,648 | 2009-09-18 | ||
| PCT/US2010/048314 WO2011034775A2 (en) | 2009-09-18 | 2010-09-09 | Methods for treating brain tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012108439A true RU2012108439A (ru) | 2013-10-27 |
Family
ID=43756836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012108439/15A RU2012108439A (ru) | 2009-09-18 | 2010-09-09 | Способы лечения опухолей головного мозга |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20110070314A1 (OSRAM) |
| EP (1) | EP2477635A4 (OSRAM) |
| JP (1) | JP2013505242A (OSRAM) |
| KR (1) | KR20120048706A (OSRAM) |
| CN (1) | CN102753188A (OSRAM) |
| AR (1) | AR078170A1 (OSRAM) |
| AU (1) | AU2010295841A1 (OSRAM) |
| BR (1) | BR112012008310A2 (OSRAM) |
| CA (1) | CA2772777A1 (OSRAM) |
| IN (1) | IN2012DN02195A (OSRAM) |
| MX (1) | MX2012002922A (OSRAM) |
| RU (1) | RU2012108439A (OSRAM) |
| SG (1) | SG179192A1 (OSRAM) |
| TW (1) | TW201114431A (OSRAM) |
| WO (1) | WO2011034775A2 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010292192B2 (en) * | 2009-09-10 | 2015-04-02 | Kominox, Inc. | Cancer stem cell-targeted and drug resistant cancer therapy |
| KR101309036B1 (ko) * | 2011-05-30 | 2013-09-16 | 주식회사 코미팜 | 방사선 민감도 증진용 약학 조성물 |
| US8781202B2 (en) * | 2012-07-26 | 2014-07-15 | International Business Machines Corporation | Tumor classification based on an analysis of a related ultrasonic attenuation map |
| US10076652B2 (en) * | 2015-08-10 | 2018-09-18 | Chang Gung University | Method for ultrasound-mediated delivery system to monitor molecular penetration |
| WO2019178643A1 (en) * | 2018-03-22 | 2019-09-26 | Komipharm International Australia Pty Ltd | Pharmaceutical composition comprising meta arsenite and method of manufacture |
| KR20220020635A (ko) * | 2020-08-12 | 2022-02-21 | 이상봉 | 탈모방지 또는 발모촉진용 외용제 조성물 |
| KR20220020637A (ko) * | 2020-08-12 | 2022-02-21 | 이상봉 | 항암화학요법이나 방사선요법으로 인한 암 환자의 탈모증을 포함한 탈모증 환자에 대하여 탈모를 방지하고 발모를 촉진하는 메타아르세나이트의 염을 함유하는 경구 투여용 약학적 조성물 |
| KR20220020633A (ko) * | 2020-08-12 | 2022-02-21 | 이상봉 | 탈모방지 또는 발모촉진용 주사제 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1391206B1 (en) * | 1997-10-15 | 2008-07-02 | Polarx Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma |
| KR20020083678A (ko) * | 2001-04-28 | 2002-11-04 | 주식회사 한국미생물연구소 | 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물 |
| ES2425418T3 (es) * | 2002-04-10 | 2013-10-15 | Komipharm International Co., Ltd. | Composición farmacéutica que comprende arsenito para el tratamiento de neoplasias |
| WO2006104292A1 (en) * | 2005-03-31 | 2006-10-05 | Komipharm International Co., Ltd. | Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts |
| EP1721615A1 (en) * | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
-
2010
- 2010-09-09 MX MX2012002922A patent/MX2012002922A/es not_active Application Discontinuation
- 2010-09-09 IN IN2195DEN2012 patent/IN2012DN02195A/en unknown
- 2010-09-09 EP EP10817682A patent/EP2477635A4/en not_active Withdrawn
- 2010-09-09 JP JP2012529803A patent/JP2013505242A/ja not_active Withdrawn
- 2010-09-09 SG SG2012018859A patent/SG179192A1/en unknown
- 2010-09-09 CN CN2010800414064A patent/CN102753188A/zh active Pending
- 2010-09-09 BR BR112012008310A patent/BR112012008310A2/pt not_active IP Right Cessation
- 2010-09-09 AU AU2010295841A patent/AU2010295841A1/en not_active Abandoned
- 2010-09-09 WO PCT/US2010/048314 patent/WO2011034775A2/en not_active Ceased
- 2010-09-09 CA CA2772777A patent/CA2772777A1/en not_active Abandoned
- 2010-09-09 KR KR1020127008137A patent/KR20120048706A/ko not_active Ceased
- 2010-09-09 RU RU2012108439/15A patent/RU2012108439A/ru not_active Application Discontinuation
- 2010-09-10 AR ARP100103326A patent/AR078170A1/es unknown
- 2010-09-10 TW TW099130699A patent/TW201114431A/zh unknown
- 2010-09-10 US US12/879,316 patent/US20110070314A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011034775A2 (en) | 2011-03-24 |
| BR112012008310A2 (pt) | 2017-06-06 |
| KR20120048706A (ko) | 2012-05-15 |
| CA2772777A1 (en) | 2011-03-24 |
| TW201114431A (en) | 2011-05-01 |
| EP2477635A4 (en) | 2013-03-27 |
| SG179192A1 (en) | 2012-05-30 |
| JP2013505242A (ja) | 2013-02-14 |
| AU2010295841A1 (en) | 2012-03-29 |
| CN102753188A (zh) | 2012-10-24 |
| IN2012DN02195A (OSRAM) | 2015-08-21 |
| EP2477635A2 (en) | 2012-07-25 |
| WO2011034775A3 (en) | 2011-10-06 |
| US20110070314A1 (en) | 2011-03-24 |
| AR078170A1 (es) | 2011-10-19 |
| MX2012002922A (es) | 2012-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012108439A (ru) | Способы лечения опухолей головного мозга | |
| EA201101507A1 (ru) | Способы лечения солидных опухолей | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA200870254A1 (ru) | Способ лечения воспалительных заболеваний | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| CR11724A (es) | Agente para tratar enfermedades | |
| EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
| CO6241170A2 (es) | Administracion de oligonucleotidos antisentido complementarios a la apolipoproteina b humana | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201490495A1 (ru) | Новые легкоразрушающиеся ингибиторы rock | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| TNSN07419A1 (en) | Methods for treating drug resistant cancer | |
| JP2014520893A5 (OSRAM) | ||
| RU2013123646A (ru) | Комбинированная композиция | |
| EA201270071A1 (ru) | Способ лечения пациента, нуждающегося в аспириновой терапии | |
| EA201590847A1 (ru) | Новые ингибиторы rock | |
| BRPI0510895A (pt) | formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t | |
| RU2015112121A (ru) | Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний | |
| AR079000A1 (es) | Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas | |
| EA201490417A1 (ru) | Новые легкоразрушающиеся ингибиторы pde 4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20141202 |